A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer

3582 Background: Apomab, a fully human affinity-matured IgG1 monoclonal antibody, is a DR5 pro-apoptotic receptor agonist that triggers the extrinsic pathway of apoptosis. DR5 is expressed both on ...